X

Trial Profile

A Multi-Center , Sequential Dose Escalation Study, Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Enlivex Therapeutics

Most Recent Events

17 Aug 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
17 Aug 2021 Planned primary completion date changed from 1 Mar 2022 to 1 Sep 2022.
17 Aug 2021 Planned initiation date changed from 1 Jun 2021 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com